Skip to main content

Pancreatic Cancer

Drug Resistance Analysis of Pancreatic Cancer Based on Universally Differentially Expressed Genes


Pancreatic ductal adenocarcinoma (PDAC) is considered one of the most aggressive malignant neoplasms, with a 12.8% five-year survival rate according to National Cancer Institute statistics. Complete surgery resection is the only possible cure for resectable PDAC, but most patients are already in an advanced stage at diagnosis. Chemotherapy with/without radiotherapy has been a mainstay strategy for treating PDAC, but it only provides a modest improvement in survival. Only 3% to 11% of patients have pathological complete responses after receiving chemotherapy with/without radiation therapy, which may be due to the high heterogeneity between patients and the ubiquitous drug resistance of PDAC.

Immune checkpoint blockade (ICB) has changed the standard of care for multiple cancers and has brought hope to pancreatic cancer patients; however, almost all tentative trials have had little effect or failed before clinical application. The most common reason for failure was the immunosuppressive tumor microenvironment (TME) resulting in low effector T cell infiltration, which is unfavorable for the immune response. We suspect that there are some common features underlying the high heterogeneity of pancreatic cancer, which could be closely related to the mechanism underlying the ineffectiveness of current therapies. It is essential to identify and target these mechanisms to improve the early diagnosis rate and therapeutic efficiency.

Conventional differentially expressed gene (DEG) screening methods for bulk tissues only compare the average expression levels between disease and control groups, which cannot show the dysregulation status of each gene in a single disease sample or the frequency of differential expression of genes in all disease samples. The gold standard for individualized DEG screening is comparing the expression levels between paired tumor and adjacent normal samples from the same patient. However, the late diagnosis and difficulty of sampling pathologically normal samples in the complicated structure of the pancreas has led to few paired samples.

To solve this problem, a robust individual DEG screening method, RankComp, has been developed to detect the dysregulation of genes in a single tumor sample relative to the normal background derived from normal samples from different studies. Thus, we can identify individual-level DEGs for unpaired tumor samples based on the aggregation of normal samples using this method. Here, we made full use of paired and unpaired PDAC samples to identify common molecular characteristics of PDAC patients to construct a robust early diagnosis model and determine the mechanisms underlying the resistance to current therapies.

In this study, using transcription profiles of paired and unpaired PDAC bulk samples, we identified individual-level DEGs in the PDAC samples and defined the genes that were dysregulated in at least 85% of the PDAC samples as universally differentially expressed genes (UDEGs). Bulk assays represent a population average, which masks the heterogeneity that exists at the single-cell level . Thus, we analyzed the expression of the UDEGs at the single-cell level to explore their roles in the formation of tumors. Finally, we investigated the potential association between the UDEGs and overall drug resistance based on GDSC resistance data, as well as their correlation with responsiveness to immunotherapy using reported immunotherapy biomarkers.

Pancreatic cancer, Pancreatitis, Pancreatic ductal adenocarcinoma, Tumor markers, CA 19-9, Chronic pancreatitis, Acute pancreatitis, Diabetes mellitus, Jaundice, Abdominal pain, Chemotherapy, Radiation therapy, Genetic mutations, KRAS mutation, Metastasis, Whipple procedure, Immunotherapy, Biliary obstruction, Pancreatic cysts, Early detection

#PancreaticCancer, #Pancreatitis, #PDAC, #TumorMarkers, #CA199, #ChronicPancreatitis, #AcutePancreatitis, #PancreaticHealth, #DiabetesAndCancer, #CancerAwareness, #PancreaticPain, #CancerResearch, #KRASMutation, #PancreaticTumor, #CancerMetastasis, #WhippleSurgery, #Immunotherapy, #CancerDiagnosis, #PancreaticScreening, #OncologyCare

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Genetics role in ovarian cancer

The Medical Minute: Genetics play big role in ovarian cancer In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die from the disease, said Dr. Shaina Bruce , a gynecologic oncologist at Penn State Cancer Institute . The median age of all patients who develop ovarian cancer is 63. Historically, women at increased risk for ovarian cancer are recommended to have their fallopian tubes and ovaries removed when they have completed having children. Taking that step to protect themselves comes at a heavy price ― surgical menopause. But Bruce said medical science is catching up with ovarian cancer. Studies could lead to new methods for preventative care and the surgery needed to lower risk may be easier than it once was. Below, during Gynecologic Cancer Awareness Month, Bruce discusses the disease and why acting to reduce your risk is worth it. What’s the connection between heredity and ovarian cancer? About 25% of all cases of ...
Post a Comment
Read more

Multifactorial Genetic Conditions

Multifactorial Genetic Conditions Multifactorial genetic conditions are disorders caused by the combined effects of multiple genes and environmental factors , rather than a single gene mutation . These conditions do not follow classic Mendelian inheritance patterns and instead result from complex gene–environment interactions . Factors such as lifestyle, nutrition, infections, stress, and exposure to toxins can significantly influence disease onset and severity in genetically susceptible individuals. Common examples include diabetes, cardiovascular diseases , neural tube defects, asthma, and many neuropsychiatric disorders. Understanding multifactorial inheritance is essential for risk prediction, preventive medicine, and personalized healthcare strategies. Multifactorial inheritance, polygenic traits, gene–environment interaction, complex diseases, genetic susceptibility, environmental risk factors, non-Mendelian inheritance, disease predisposition, polygenic risk score, precision ...
Post a Comment
Read more

X chromosome

Gene on the X chromosome may help explain high multiple sclerosis rates in women Brain inflammation may be fueled by a gene on the X chromosome, a new study in mice suggests. And in female mice, who carry two X chromosomes, a diabetes drug called metformin may work to counteract that inflammation. If these findings bear out in later studies, they could help to unravel the long-standing mystery of why women, who have two copies of this inflammation-driving gene, are more prone to certain autoimmune diseases, particularly after menopause. A disparity between the sexes Our bodies are patrolled by immune cells that provide protection against bacteria and viruses, but sometimes, these defenses turn on us. In the autoimmune disorder multiple sclerosis (MS), for instance, the immune system attacks myelin, the fatty insulation surrounding the nerve fibers in the brain and spinal cord. This leads to symptoms such as muscle weakness and difficulty walking, as well issues with memory and thinking...
Post a Comment
Read more